• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450
• 3. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

Research Brief on 5-Bromo-4-octylpyrimidine (CAS: 1033201-80-7): Recent Advances and Applications in Chemical Biology and Medicine

5-Bromo-4-octylpyrimidine (CAS: 1033201-80-7) is a brominated pyrimidine derivative that has garnered significant attention in recent years due to its potential applications in chemical biology and medicinal chemistry. This compound, characterized by its unique octyl side chain and bromine substitution, has been explored for its role in modulating biological pathways, particularly in the context of enzyme inhibition and drug discovery. Recent studies have highlighted its utility as a versatile building block in the synthesis of more complex bioactive molecules, as well as its direct pharmacological effects.

One of the key areas of research involving 5-Bromo-4-octylpyrimidine is its application in the development of kinase inhibitors. Kinases are critical enzymes involved in signal transduction and are often targeted in cancer therapy. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of 5-Bromo-4-octylpyrimidine exhibited potent inhibitory activity against specific tyrosine kinases, with IC50 values in the nanomolar range. The study further elucidated the structural basis for this inhibition, revealing that the bromine atom and the octyl chain play crucial roles in binding to the kinase active site.

In addition to its kinase inhibitory properties, 5-Bromo-4-octylpyrimidine has also been investigated for its potential as an antimicrobial agent. A recent preprint on bioRxiv reported that this compound displayed broad-spectrum activity against several drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. The mechanism of action appears to involve disruption of bacterial cell membrane integrity, a finding that could pave the way for novel antibiotic development.

The synthetic versatility of 5-Bromo-4-octylpyrimidine has also been a focus of recent research. A 2024 paper in Organic Letters described an efficient, one-pot synthesis method for this compound, significantly improving its accessibility for further studies. The new synthetic route employs a palladium-catalyzed cross-coupling reaction, which offers higher yields and better scalability compared to traditional methods. This advancement is expected to facilitate more extensive exploration of the compound's biological activities and potential therapeutic applications.

Looking ahead, the unique structural features of 5-Bromo-4-octylpyrimidine continue to inspire innovative research directions. Current investigations are exploring its use in targeted drug delivery systems, where the octyl chain could serve as an anchor for lipid-based nanoparticles. Preliminary results from these studies suggest that the compound may enhance the bioavailability of poorly soluble drugs, addressing a significant challenge in pharmaceutical development. As research progresses, 5-Bromo-4-octylpyrimidine is poised to make important contributions to both fundamental chemical biology and applied medicinal chemistry.

• 951884-36-9(5-Bromo-4-ethylpyrimidine)
• 951884-30-3(5-bromo-4-sec-butylpyrimidine)
• 4595-64-6(5-Bromo-4-butylpyrimidine)
• 951884-24-5(5-Bromo-4-isooctylpyrimidine)
• 951884-44-9(5-Bromo-4-heptylpyrimidine)
• 951884-26-7(5-bromo-4-propylpyrimidine)
• 941294-28-6(5-bromo-4-cyclohexylpyrimidine)
• 951884-42-7(5-Bromo-4-isopentylpyrimidine)
• 951884-28-9(5-bromo-4-isopropylpyrimidine)
• 951884-32-5(5-bromo-4-cyclopentylpyrimidine)